Level/ Type |
Code |
Display Name |
Code System |
Designations |
Description |
0‑L |
A
|
ALIMENTARY TRACT AND METABOLISM
|
WHO Anatomical Therapeutic Chemical classification |
|
ALIMENTARY TRACT AND METABOLISM |
0‑L |
A01
|
STOMATOLOGICAL PREPARATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
STOMATOLOGICAL PREPARATIONS |
0‑L |
A01A
|
STOMATOLOGICAL PREPARATIONS
|
WHO Anatomical Therapeutic Chemical classification |
|
STOMATOLOGICAL PREPARATIONS |
0‑L |
A01AA
|
Caries prophylactic agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Caries prophylactic agents |
0‑L |
A01AA01
|
sodium fluoride
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium fluoride |
0‑L |
A01AA02
|
sodium monofluorophosphate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium monofluorophosphate |
0‑L |
A01AA03
|
olaflur
|
WHO Anatomical Therapeutic Chemical classification |
|
olaflur |
0‑L |
A01AA04
|
stannous fluoride
|
WHO Anatomical Therapeutic Chemical classification |
|
stannous fluoride |
0‑L |
A01AA30
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
0‑L |
A01AA51
|
sodium fluoride, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium fluoride, combinations |
0‑L |
A01AB
|
Antiinfectives and antiseptics for local oral treatment
|
WHO Anatomical Therapeutic Chemical classification |
|
Antiinfectives and antiseptics for local oral treatment |
0‑L |
A01AB02
|
hydrogen peroxide
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrogen peroxide |
0‑L |
A01AB03
|
chlorhexidine
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorhexidine |
0‑L |
A01AB04
|
amphotericin B
|
WHO Anatomical Therapeutic Chemical classification |
|
amphotericin B |
0‑L |
A01AB05
|
polynoxylin
|
WHO Anatomical Therapeutic Chemical classification |
|
polynoxylin |
0‑L |
A01AB06
|
domiphen
|
WHO Anatomical Therapeutic Chemical classification |
|
domiphen |
0‑L |
A01AB07
|
oxyquinoline
|
WHO Anatomical Therapeutic Chemical classification |
|
oxyquinoline |
0‑L |
A01AB08
|
neomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
neomycin |
0‑L |
A01AB09
|
miconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
miconazole |
0‑L |
A01AB10
|
natamycin
|
WHO Anatomical Therapeutic Chemical classification |
|
natamycin |
0‑L |
A01AB11
|
various
|
WHO Anatomical Therapeutic Chemical classification |
|
various |
0‑L |
A01AB12
|
hexetidine
|
WHO Anatomical Therapeutic Chemical classification |
|
hexetidine |
0‑L |
A01AB13
|
tetracycline
|
WHO Anatomical Therapeutic Chemical classification |
|
tetracycline |
0‑L |
A01AB14
|
benzoxonium chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
benzoxonium chloride |
0‑L |
A01AB15
|
tibezonium iodide
|
WHO Anatomical Therapeutic Chemical classification |
|
tibezonium iodide |
0‑L |
A01AB16
|
mepartricin
|
WHO Anatomical Therapeutic Chemical classification |
|
mepartricin |
0‑L |
A01AB17
|
metronidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
metronidazole |
0‑L |
A01AB18
|
clotrimazole
|
WHO Anatomical Therapeutic Chemical classification |
|
clotrimazole |
0‑L |
A01AB19
|
sodium perborate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium perborate |
0‑L |
A01AB21
|
chlortetracycline
|
WHO Anatomical Therapeutic Chemical classification |
|
chlortetracycline |
0‑L |
A01AB22
|
doxycycline
|
WHO Anatomical Therapeutic Chemical classification |
|
doxycycline |
0‑L |
A01AB23
|
minocycline
|
WHO Anatomical Therapeutic Chemical classification |
|
minocycline |
0‑L |
A01AC
|
Corticosteroids for local oral treatment
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids for local oral treatment |
0‑L |
A01AC01
|
triamcinolone
|
WHO Anatomical Therapeutic Chemical classification |
|
triamcinolone |
0‑L |
A01AC02
|
dexamethasone
|
WHO Anatomical Therapeutic Chemical classification |
|
dexamethasone |
0‑L |
A01AC03
|
hydrocortisone
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrocortisone |
0‑L |
A01AC54
|
prednisolone, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
prednisolone, combinations |
0‑L |
A01AD
|
Other agents for local oral treatment
|
WHO Anatomical Therapeutic Chemical classification |
|
Other agents for local oral treatment |
0‑L |
A01AD01
|
epinephrine
|
WHO Anatomical Therapeutic Chemical classification |
|
epinephrine |
0‑L |
A01AD02
|
benzydamine
|
WHO Anatomical Therapeutic Chemical classification |
|
benzydamine |
0‑L |
A01AD05
|
acetylsalicylic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
acetylsalicylic acid |
0‑L |
A01AD06
|
adrenalone
|
WHO Anatomical Therapeutic Chemical classification |
|
adrenalone |
0‑L |
A01AD07
|
amlexanox
|
WHO Anatomical Therapeutic Chemical classification |
|
amlexanox |
0‑L |
A01AD08
|
becaplermin
|
WHO Anatomical Therapeutic Chemical classification |
|
becaplermin |
0‑L |
A01AD11
|
various
|
WHO Anatomical Therapeutic Chemical classification |
|
various |
0‑L |
A02
|
DRUGS FOR ACID RELATED DISORDERS
|
WHO Anatomical Therapeutic Chemical classification |
|
DRUGS FOR ACID RELATED DISORDERS |
0‑L |
A02A
|
ANTACIDS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTACIDS |
0‑L |
A02AA
|
Magnesium compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Magnesium compounds |
0‑L |
A02AA01
|
magnesium carbonate
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium carbonate |
0‑L |
A02AA02
|
magnesium oxide
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium oxide |
0‑L |
A02AA03
|
magnesium peroxide
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium peroxide |
0‑L |
A02AA04
|
magnesium hydroxide
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium hydroxide |
0‑L |
A02AA05
|
magnesium silicate
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium silicate |
0‑L |
A02AA10
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
0‑L |
A02AB
|
Aluminium compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Aluminium compounds |
0‑L |
A02AB01
|
aluminium hydroxide
|
WHO Anatomical Therapeutic Chemical classification |
|
aluminium hydroxide |
0‑L |
A02AB02
|
algeldrate
|
WHO Anatomical Therapeutic Chemical classification |
|
algeldrate |
0‑L |
A02AB03
|
aluminium phosphate
|
WHO Anatomical Therapeutic Chemical classification |
|
aluminium phosphate |
0‑L |
A02AB04
|
dihydroxialumini sodium carbonate
|
WHO Anatomical Therapeutic Chemical classification |
|
dihydroxialumini sodium carbonate |
0‑L |
A02AB05
|
aluminium acetoacetate
|
WHO Anatomical Therapeutic Chemical classification |
|
aluminium acetoacetate |
0‑L |
A02AB06
|
aloglutamol
|
WHO Anatomical Therapeutic Chemical classification |
|
aloglutamol |
0‑L |
A02AB07
|
aluminium glycinate
|
WHO Anatomical Therapeutic Chemical classification |
|
aluminium glycinate |
0‑L |
A02AB10
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
0‑L |
A02AC
|
Calcium compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Calcium compounds |
0‑L |
A02AC01
|
calcium carbonate
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium carbonate |
0‑L |
A02AC02
|
calcium silicate
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium silicate |
0‑L |
A02AC10
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
0‑L |
A02AD
|
Combinations and complexes of aluminium, calcium and magnesium compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Combinations and complexes of aluminium, calcium and magnesium compounds |
0‑L |
A02AD01
|
ordinary salt combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
ordinary salt combinations |
0‑L |
A02AD02
|
magaldrate
|
WHO Anatomical Therapeutic Chemical classification |
|
magaldrate |
0‑L |
A02AD03
|
almagate
|
WHO Anatomical Therapeutic Chemical classification |
|
almagate |
0‑L |
A02AD04
|
hydrotalcite
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrotalcite |
0‑L |
A02AD05
|
almasilate
|
WHO Anatomical Therapeutic Chemical classification |
|
almasilate |
0‑L |
A02AF
|
Antacids with antiflatulents
|
WHO Anatomical Therapeutic Chemical classification |
|
Antacids with antiflatulents |
0‑L |
A02AF01
|
magaldrate and antiflatulents
|
WHO Anatomical Therapeutic Chemical classification |
|
magaldrate and antiflatulents |
0‑L |
A02AF02
|
ordinary salt combinations and antiflatulents
|
WHO Anatomical Therapeutic Chemical classification |
|
ordinary salt combinations and antiflatulents |
0‑L |
A02AG
|
Antacids with antispasmodics
|
WHO Anatomical Therapeutic Chemical classification |
|
Antacids with antispasmodics |
0‑L |
A02AH
|
Antacids with sodium bicarbonate
|
WHO Anatomical Therapeutic Chemical classification |
|
Antacids with sodium bicarbonate |
0‑L |
A02AX
|
Antacids, other combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
Antacids, other combinations |
0‑L |
A02B
|
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
|
WHO Anatomical Therapeutic Chemical classification |
|
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) |
0‑L |
A02BA
|
H2-receptor antagonists
|
WHO Anatomical Therapeutic Chemical classification |
|
H2-receptor antagonists |
0‑L |
A02BA01
|
cimetidine
|
WHO Anatomical Therapeutic Chemical classification |
|
cimetidine |
0‑L |
A02BA02
|
ranitidine
|
WHO Anatomical Therapeutic Chemical classification |
|
ranitidine |
0‑L |
A02BA03
|
famotidine
|
WHO Anatomical Therapeutic Chemical classification |
|
famotidine |
0‑L |
A02BA04
|
nizatidine
|
WHO Anatomical Therapeutic Chemical classification |
|
nizatidine |
0‑L |
A02BA05
|
niperotidine
|
WHO Anatomical Therapeutic Chemical classification |
|
niperotidine |
0‑L |
A02BA06
|
roxatidine
|
WHO Anatomical Therapeutic Chemical classification |
|
roxatidine |
0‑L |
A02BA07
|
ranitidine bismuth citrate
|
WHO Anatomical Therapeutic Chemical classification |
|
ranitidine bismuth citrate |
0‑L |
A02BA08
|
lafutidine
|
WHO Anatomical Therapeutic Chemical classification |
|
lafutidine |
0‑L |
A02BA51
|
cimetidine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
cimetidine, combinations |
0‑L |
A02BA53
|
famotidine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
famotidine, combinations |
0‑L |
A02BB
|
Prostaglandins
|
WHO Anatomical Therapeutic Chemical classification |
|
Prostaglandins |
0‑L |
A02BB01
|
misoprostol
|
WHO Anatomical Therapeutic Chemical classification |
|
misoprostol |
0‑L |
A02BB02
|
enprostil
|
WHO Anatomical Therapeutic Chemical classification |
|
enprostil |
0‑L |
A02BC
|
Proton pump inhibitors
|
WHO Anatomical Therapeutic Chemical classification |
|
Proton pump inhibitors |
0‑L |
A02BC01
|
omeprazole
|
WHO Anatomical Therapeutic Chemical classification |
|
omeprazole |
0‑L |
A02BC02
|
pantoprazole
|
WHO Anatomical Therapeutic Chemical classification |
|
pantoprazole |
0‑L |
A02BC03
|
lansoprazole
|
WHO Anatomical Therapeutic Chemical classification |
|
lansoprazole |
0‑L |
A02BC04
|
rabeprazole
|
WHO Anatomical Therapeutic Chemical classification |
|
rabeprazole |
0‑L |
A02BC05
|
esomeprazole
|
WHO Anatomical Therapeutic Chemical classification |
|
esomeprazole |
0‑L |
A02BC06
|
dexlansoprazole
|
WHO Anatomical Therapeutic Chemical classification |
|
dexlansoprazole |
0‑L |
A02BC07
|
dexrabeprazole
|
WHO Anatomical Therapeutic Chemical classification |
|
dexrabeprazole |
0‑L |
A02BC53
|
lansoprazole, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
lansoprazole, combinations |
0‑L |
A02BC54
|
rabeprazole, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
rabeprazole, combinations |
0‑L |
A02BD
|
Combinations for eradication of Helicobacter pylori
|
WHO Anatomical Therapeutic Chemical classification |
|
Combinations for eradication of Helicobacter pylori |
0‑L |
A02BD01
|
omeprazole, amoxicillin and metronidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
omeprazole, amoxicillin and metronidazole |
0‑L |
A02BD02
|
lansoprazole, tetracycline and metronidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
lansoprazole, tetracycline and metronidazole |
0‑L |
A02BD03
|
lansoprazole, amoxicillin and metronidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
lansoprazole, amoxicillin and metronidazole |
0‑L |
A02BD04
|
pantoprazole, amoxicillin and clarithromycin
|
WHO Anatomical Therapeutic Chemical classification |
|
pantoprazole, amoxicillin and clarithromycin |
0‑L |
A02BD05
|
omeprazole, amoxicillin and clarithromycin
|
WHO Anatomical Therapeutic Chemical classification |
|
omeprazole, amoxicillin and clarithromycin |
0‑L |
A02BD06
|
esomeprazole, amoxicillin and clarithromycin
|
WHO Anatomical Therapeutic Chemical classification |
|
esomeprazole, amoxicillin and clarithromycin |
0‑L |
A02BD07
|
lansoprazole, amoxicillin and clarithromycin
|
WHO Anatomical Therapeutic Chemical classification |
|
lansoprazole, amoxicillin and clarithromycin |
0‑L |
A02BD08
|
bismuth subcitrate, tetracycline and metronidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
bismuth subcitrate, tetracycline and metronidazole |
0‑L |
A02BD09
|
lansoprazole, clarithromycin and tinidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
lansoprazole, clarithromycin and tinidazole |
0‑L |
A02BD10
|
lansoprazole, amoxicillin and levofloxacin
|
WHO Anatomical Therapeutic Chemical classification |
|
lansoprazole, amoxicillin and levofloxacin |
0‑L |
A02BD11
|
pantoprazole, amoxicillin, clarithromycin and metronidazole
|
WHO Anatomical Therapeutic Chemical classification |
|
pantoprazole, amoxicillin, clarithromycin and metronidazole |
0‑L |
A02BX
|
Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
|
WHO Anatomical Therapeutic Chemical classification |
|
Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) |
0‑L |
A02BX01
|
carbenoxolone
|
WHO Anatomical Therapeutic Chemical classification |
|
carbenoxolone |
0‑L |
A02BX02
|
sucralfate
|
WHO Anatomical Therapeutic Chemical classification |
|
sucralfate |
0‑L |
A02BX03
|
pirenzepine
|
WHO Anatomical Therapeutic Chemical classification |
|
pirenzepine |
0‑L |
A02BX04
|
methiosulfonium chloride
|
WHO Anatomical Therapeutic Chemical classification |
|
methiosulfonium chloride |
0‑L |
A02BX05
|
bismuth subcitrate
|
WHO Anatomical Therapeutic Chemical classification |
|
bismuth subcitrate |
0‑L |
A02BX06
|
proglumide
|
WHO Anatomical Therapeutic Chemical classification |
|
proglumide |
0‑L |
A02BX07
|
gefarnate
|
WHO Anatomical Therapeutic Chemical classification |
|
gefarnate |
0‑L |
A02BX08
|
sulglicotide
|
WHO Anatomical Therapeutic Chemical classification |
|
sulglicotide |
0‑L |
A02BX09
|
acetoxolone
|
WHO Anatomical Therapeutic Chemical classification |
|
acetoxolone |
0‑L |
A02BX10
|
zolimidine
|
WHO Anatomical Therapeutic Chemical classification |
|
zolimidine |
0‑L |
A02BX11
|
troxipide
|
WHO Anatomical Therapeutic Chemical classification |
|
troxipide |
0‑L |
A02BX12
|
bismuth subnitrate
|
WHO Anatomical Therapeutic Chemical classification |
|
bismuth subnitrate |
0‑L |
A02BX13
|
alginic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
alginic acid |
0‑L |
A02BX51
|
carbenoxolone, combinations excl. psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
carbenoxolone, combinations excl. psycholeptics |
0‑L |
A02BX71
|
carbenoxolone, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
carbenoxolone, combinations with psycholeptics |
0‑L |
A02BX77
|
gefarnate, combinations with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
gefarnate, combinations with psycholeptics |
0‑L |
A02X
|
OTHER DRUGS FOR ACID RELATED DISORDERS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER DRUGS FOR ACID RELATED DISORDERS |
0‑L |
A03
|
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
|
WHO Anatomical Therapeutic Chemical classification |
|
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS |
0‑L |
A03A
|
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
|
WHO Anatomical Therapeutic Chemical classification |
|
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS |
0‑L |
A03AA
|
Synthetic anticholinergics, esters with tertiary amino group
|
WHO Anatomical Therapeutic Chemical classification |
|
Synthetic anticholinergics, esters with tertiary amino group |
0‑L |
A03AA01
|
oxyphencyclimine
|
WHO Anatomical Therapeutic Chemical classification |
|
oxyphencyclimine |
0‑L |
A03AA03
|
camylofin
|
WHO Anatomical Therapeutic Chemical classification |
|
camylofin |
0‑L |
A03AA04
|
mebeverine
|
WHO Anatomical Therapeutic Chemical classification |
|
mebeverine |
0‑L |
A03AA05
|
trimebutine
|
WHO Anatomical Therapeutic Chemical classification |
|
trimebutine |
0‑L |
A03AA06
|
rociverine
|
WHO Anatomical Therapeutic Chemical classification |
|
rociverine |
0‑L |
A03AA07
|
dicycloverine
|
WHO Anatomical Therapeutic Chemical classification |
|
dicycloverine |
0‑L |
A03AA08
|
dihexyverine
|
WHO Anatomical Therapeutic Chemical classification |
|
dihexyverine |
0‑L |
A03AA09
|
difemerine
|
WHO Anatomical Therapeutic Chemical classification |
|
difemerine |
0‑L |
A03AA30
|
piperidolate
|
WHO Anatomical Therapeutic Chemical classification |
|
piperidolate |
0‑L |
A03AB
|
Synthetic anticholinergics, quaternary ammonium compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Synthetic anticholinergics, quaternary ammonium compounds |
0‑L |
A03AB01
|
benzilone
|
WHO Anatomical Therapeutic Chemical classification |
|
benzilone |
0‑L |
A03AB02
|
glycopyrronium bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
glycopyrronium bromide |
0‑L |
A03AB03
|
oxyphenonium
|
WHO Anatomical Therapeutic Chemical classification |
|
oxyphenonium |
0‑L |
A03AB04
|
penthienate
|
WHO Anatomical Therapeutic Chemical classification |
|
penthienate |
0‑L |
A03AB05
|
propantheline
|
WHO Anatomical Therapeutic Chemical classification |
|
propantheline |
0‑L |
A03AB06
|
otilonium bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
otilonium bromide |
0‑L |
A03AB07
|
methantheline
|
WHO Anatomical Therapeutic Chemical classification |
|
methantheline |
0‑L |
A03AB08
|
tridihexethyl
|
WHO Anatomical Therapeutic Chemical classification |
|
tridihexethyl |
0‑L |
A03AB09
|
isopropamide
|
WHO Anatomical Therapeutic Chemical classification |
|
isopropamide |
0‑L |
A03AB10
|
hexocyclium
|
WHO Anatomical Therapeutic Chemical classification |
|
hexocyclium |
0‑L |
A03AB11
|
poldine
|
WHO Anatomical Therapeutic Chemical classification |
|
poldine |
0‑L |
A03AB12
|
mepenzolate
|
WHO Anatomical Therapeutic Chemical classification |
|
mepenzolate |
0‑L |
A03AB13
|
bevonium
|
WHO Anatomical Therapeutic Chemical classification |
|
bevonium |
0‑L |
A03AB14
|
pipenzolate
|
WHO Anatomical Therapeutic Chemical classification |
|
pipenzolate |
0‑L |
A03AB15
|
diphemanil
|
WHO Anatomical Therapeutic Chemical classification |
|
diphemanil |
0‑L |
A03AB16
|
(2-benzhydryloxyethyl)diethyl-methylammonium iodide
|
WHO Anatomical Therapeutic Chemical classification |
|
(2-benzhydryloxyethyl)diethyl-methylammonium iodide |
0‑L |
A03AB17
|
tiemonium iodide
|
WHO Anatomical Therapeutic Chemical classification |
|
tiemonium iodide |
0‑L |
A03AB18
|
prifinium bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
prifinium bromide |
0‑L |
A03AB19
|
timepidium bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
timepidium bromide |
0‑L |
A03AB21
|
fenpiverinium
|
WHO Anatomical Therapeutic Chemical classification |
|
fenpiverinium |
0‑L |
A03AB53
|
oxyphenonium, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
oxyphenonium, combinations |
0‑L |
A03AC
|
Synthetic antispasmodics, amides with tertiary amines
|
WHO Anatomical Therapeutic Chemical classification |
|
Synthetic antispasmodics, amides with tertiary amines |
0‑L |
A03AC02
|
dimethylaminopropionylphenothiazine
|
WHO Anatomical Therapeutic Chemical classification |
|
dimethylaminopropionylphenothiazine |
0‑L |
A03AC04
|
nicofetamide
|
WHO Anatomical Therapeutic Chemical classification |
|
nicofetamide |
0‑L |
A03AC05
|
tiropramide
|
WHO Anatomical Therapeutic Chemical classification |
|
tiropramide |
0‑L |
A03AD
|
Papaverine and derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Papaverine and derivatives |
0‑L |
A03AD01
|
papaverine
|
WHO Anatomical Therapeutic Chemical classification |
|
papaverine |
0‑L |
A03AD02
|
drotaverine
|
WHO Anatomical Therapeutic Chemical classification |
|
drotaverine |
0‑L |
A03AD30
|
moxaverine
|
WHO Anatomical Therapeutic Chemical classification |
|
moxaverine |
0‑L |
A03AE
|
Serotonin receptor antagonists
|
WHO Anatomical Therapeutic Chemical classification |
|
Serotonin receptor antagonists |
0‑L |
A03AE01
|
alosetron
|
WHO Anatomical Therapeutic Chemical classification |
|
alosetron |
0‑L |
A03AE03
|
cilansetron
|
WHO Anatomical Therapeutic Chemical classification |
|
cilansetron |
0‑L |
A03AX
|
Other drugs for functional gastrointestinal disorders
|
WHO Anatomical Therapeutic Chemical classification |
|
Other drugs for functional gastrointestinal disorders |
0‑L |
A03AX01
|
fenpiprane
|
WHO Anatomical Therapeutic Chemical classification |
|
fenpiprane |
0‑L |
A03AX02
|
diisopromine
|
WHO Anatomical Therapeutic Chemical classification |
|
diisopromine |
0‑L |
A03AX03
|
chlorbenzoxamine
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorbenzoxamine |
0‑L |
A03AX04
|
pinaverium
|
WHO Anatomical Therapeutic Chemical classification |
|
pinaverium |
0‑L |
A03AX05
|
fenoverine
|
WHO Anatomical Therapeutic Chemical classification |
|
fenoverine |
0‑L |
A03AX06
|
idanpramine
|
WHO Anatomical Therapeutic Chemical classification |
|
idanpramine |
0‑L |
A03AX07
|
proxazole
|
WHO Anatomical Therapeutic Chemical classification |
|
proxazole |
0‑L |
A03AX08
|
alverine
|
WHO Anatomical Therapeutic Chemical classification |
|
alverine |
0‑L |
A03AX09
|
trepibutone
|
WHO Anatomical Therapeutic Chemical classification |
|
trepibutone |
0‑L |
A03AX10
|
isometheptene
|
WHO Anatomical Therapeutic Chemical classification |
|
isometheptene |
0‑L |
A03AX11
|
caroverine
|
WHO Anatomical Therapeutic Chemical classification |
|
caroverine |
0‑L |
A03AX12
|
phloroglucinol
|
WHO Anatomical Therapeutic Chemical classification |
|
phloroglucinol |
0‑L |
A03AX13
|
silicones
|
WHO Anatomical Therapeutic Chemical classification |
|
silicones |
0‑L |
A03AX14
|
valethamate
|
WHO Anatomical Therapeutic Chemical classification |
|
valethamate |
0‑L |
A03AX30
|
trimethyldiphenylpropylamine
|
WHO Anatomical Therapeutic Chemical classification |
|
trimethyldiphenylpropylamine |
0‑L |
A03AX58
|
alverine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
alverine, combinations |
0‑L |
A03B
|
BELLADONNA AND DERIVATIVES, PLAIN
|
WHO Anatomical Therapeutic Chemical classification |
|
BELLADONNA AND DERIVATIVES, PLAIN |
0‑L |
A03BA
|
Belladonna alkaloids, tertiary amines
|
WHO Anatomical Therapeutic Chemical classification |
|
Belladonna alkaloids, tertiary amines |
0‑L |
A03BA01
|
atropine
|
WHO Anatomical Therapeutic Chemical classification |
|
atropine |
0‑L |
A03BA03
|
hyoscyamine
|
WHO Anatomical Therapeutic Chemical classification |
|
hyoscyamine |
0‑L |
A03BA04
|
belladonna total alkaloids
|
WHO Anatomical Therapeutic Chemical classification |
|
belladonna total alkaloids |
0‑L |
A03BB
|
Belladonna alkaloids, semisynthetic, quaternary ammonium compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
Belladonna alkaloids, semisynthetic, quaternary ammonium compounds |
0‑L |
A03BB01
|
butylscopolamine
|
WHO Anatomical Therapeutic Chemical classification |
|
butylscopolamine |
0‑L |
A03BB02
|
methylatropine
|
WHO Anatomical Therapeutic Chemical classification |
|
methylatropine |
0‑L |
A03BB03
|
methylscopolamine
|
WHO Anatomical Therapeutic Chemical classification |
|
methylscopolamine |
0‑L |
A03BB04
|
fentonium
|
WHO Anatomical Therapeutic Chemical classification |
|
fentonium |
0‑L |
A03BB05
|
cimetropium bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
cimetropium bromide |
0‑L |
A03C
|
ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS |
0‑L |
A03CA
|
Synthetic anticholinergic agents in combination with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
Synthetic anticholinergic agents in combination with psycholeptics |
0‑L |
A03CA01
|
isopropamide and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
isopropamide and psycholeptics |
0‑L |
A03CA02
|
clidinium and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
clidinium and psycholeptics |
0‑L |
A03CA03
|
oxyphencyclimine and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
oxyphencyclimine and psycholeptics |
0‑L |
A03CA04
|
otilonium bromide and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
otilonium bromide and psycholeptics |
0‑L |
A03CA05
|
glycopyrronium bromide and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
glycopyrronium bromide and psycholeptics |
0‑L |
A03CA06
|
bevonium and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
bevonium and psycholeptics |
0‑L |
A03CA07
|
ambutonium and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
ambutonium and psycholeptics |
0‑L |
A03CA08
|
diphemanil and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
diphemanil and psycholeptics |
0‑L |
A03CA09
|
pipenzolate and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
pipenzolate and psycholeptics |
0‑L |
A03CA30
|
emepronium and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
emepronium and psycholeptics |
0‑L |
A03CA34
|
propantheline and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
propantheline and psycholeptics |
0‑L |
A03CB
|
Belladonna and derivatives in combination with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
Belladonna and derivatives in combination with psycholeptics |
0‑L |
A03CB01
|
methylscopolamine and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
methylscopolamine and psycholeptics |
0‑L |
A03CB02
|
belladonna total alkaloids and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
belladonna total alkaloids and psycholeptics |
0‑L |
A03CB03
|
atropine and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
atropine and psycholeptics |
0‑L |
A03CB04
|
methylhomatropine and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
methylhomatropine and psycholeptics |
0‑L |
A03CB31
|
hyoscyamine and psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
hyoscyamine and psycholeptics |
0‑L |
A03CC
|
Other antispasmodics in combination with psycholeptics
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antispasmodics in combination with psycholeptics |
0‑L |
A03D
|
ANTISPASMODICS IN COMBINATION WITH ANALGESICS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTISPASMODICS IN COMBINATION WITH ANALGESICS |
0‑L |
A03DA
|
Synthetic anticholinergic agents in combination with analgesics
|
WHO Anatomical Therapeutic Chemical classification |
|
Synthetic anticholinergic agents in combination with analgesics |
0‑L |
A03DA01
|
tropenzilone and analgesics
|
WHO Anatomical Therapeutic Chemical classification |
|
tropenzilone and analgesics |
0‑L |
A03DA02
|
pitofenone and analgesics
|
WHO Anatomical Therapeutic Chemical classification |
|
pitofenone and analgesics |
0‑L |
A03DA03
|
bevonium and analgesics
|
WHO Anatomical Therapeutic Chemical classification |
|
bevonium and analgesics |
0‑L |
A03DA04
|
ciclonium and analgesics
|
WHO Anatomical Therapeutic Chemical classification |
|
ciclonium and analgesics |
0‑L |
A03DA05
|
camylofin and analgesics
|
WHO Anatomical Therapeutic Chemical classification |
|
camylofin and analgesics |
0‑L |
A03DA06
|
trospium and analgesics
|
WHO Anatomical Therapeutic Chemical classification |
|
trospium and analgesics |
0‑L |
A03DA07
|
tiemonium iodide and analgesics
|
WHO Anatomical Therapeutic Chemical classification |
|
tiemonium iodide and analgesics |
0‑L |
A03DB
|
Belladonna and derivatives in combination with analgesics
|
WHO Anatomical Therapeutic Chemical classification |
|
Belladonna and derivatives in combination with analgesics |
0‑L |
A03DB04
|
butylscopolamine and analgesics
|
WHO Anatomical Therapeutic Chemical classification |
|
butylscopolamine and analgesics |
0‑L |
A03DC
|
Other antispasmodics in combination with analgesics
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antispasmodics in combination with analgesics |
0‑L |
A03E
|
ANTISPASMODICS AND ANTICHOLINERGICS IN COMBINATION WITH OTHER DRUGS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTISPASMODICS AND ANTICHOLINERGICS IN COMBINATION WITH OTHER DRUGS |
0‑L |
A03EA
|
Antispasmodics, psycholeptics and analgesics in combination
|
WHO Anatomical Therapeutic Chemical classification |
|
Antispasmodics, psycholeptics and analgesics in combination |
0‑L |
A03ED
|
Antispasmodics in combination with other drugs
|
WHO Anatomical Therapeutic Chemical classification |
|
Antispasmodics in combination with other drugs |
0‑L |
A03F
|
PROPULSIVES
|
WHO Anatomical Therapeutic Chemical classification |
|
PROPULSIVES |
0‑L |
A03FA
|
Propulsives
|
WHO Anatomical Therapeutic Chemical classification |
|
Propulsives |
0‑L |
A03FA01
|
metoclopramide
|
WHO Anatomical Therapeutic Chemical classification |
|
metoclopramide |
0‑L |
A03FA02
|
cisapride
|
WHO Anatomical Therapeutic Chemical classification |
|
cisapride |
0‑L |
A03FA03
|
domperidone
|
WHO Anatomical Therapeutic Chemical classification |
|
domperidone |
0‑L |
A03FA04
|
bromopride
|
WHO Anatomical Therapeutic Chemical classification |
|
bromopride |
0‑L |
A03FA05
|
alizapride
|
WHO Anatomical Therapeutic Chemical classification |
|
alizapride |
0‑L |
A03FA06
|
clebopride
|
WHO Anatomical Therapeutic Chemical classification |
|
clebopride |
0‑L |
A03FA07
|
itopride
|
WHO Anatomical Therapeutic Chemical classification |
|
itopride |
0‑L |
A03FA08
|
cinitapride
|
WHO Anatomical Therapeutic Chemical classification |
|
cinitapride |
0‑L |
A04
|
ANTIEMETICS AND ANTINAUSEANTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIEMETICS AND ANTINAUSEANTS |
0‑L |
A04A
|
ANTIEMETICS AND ANTINAUSEANTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIEMETICS AND ANTINAUSEANTS |
0‑L |
A04AA
|
Serotonin (5HT3) antagonists
|
WHO Anatomical Therapeutic Chemical classification |
|
Serotonin (5HT3) antagonists |
0‑L |
A04AA01
|
ondansetron
|
WHO Anatomical Therapeutic Chemical classification |
|
ondansetron |
0‑L |
A04AA02
|
granisetron
|
WHO Anatomical Therapeutic Chemical classification |
|
granisetron |
0‑L |
A04AA03
|
tropisetron
|
WHO Anatomical Therapeutic Chemical classification |
|
tropisetron |
0‑L |
A04AA04
|
dolasetron
|
WHO Anatomical Therapeutic Chemical classification |
|
dolasetron |
0‑L |
A04AA05
|
palonosetron
|
WHO Anatomical Therapeutic Chemical classification |
|
palonosetron |
0‑L |
A04AA55
|
palonosetron, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
palonosetron, combinations |
0‑L |
A04AD
|
Other antiemetics
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antiemetics |
0‑L |
A04AD01
|
scopolamine
|
WHO Anatomical Therapeutic Chemical classification |
|
scopolamine |
0‑L |
A04AD02
|
cerium oxalate
|
WHO Anatomical Therapeutic Chemical classification |
|
cerium oxalate |
0‑L |
A04AD04
|
chlorobutanol
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorobutanol |
0‑L |
A04AD05
|
metopimazine
|
WHO Anatomical Therapeutic Chemical classification |
|
metopimazine |
0‑L |
A04AD10
|
dronabinol
|
WHO Anatomical Therapeutic Chemical classification |
|
dronabinol |
0‑L |
A04AD11
|
nabilone
|
WHO Anatomical Therapeutic Chemical classification |
|
nabilone |
0‑L |
A04AD12
|
aprepitant
|
WHO Anatomical Therapeutic Chemical classification |
|
aprepitant |
0‑L |
A04AD13
|
casopitant
|
WHO Anatomical Therapeutic Chemical classification |
|
casopitant |
0‑L |
A04AD14
|
rolapitant
|
WHO Anatomical Therapeutic Chemical classification |
|
rolapitant |
0‑L |
A04AD51
|
scopolamine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
scopolamine, combinations |
0‑L |
A04AD54
|
chlorobutanol, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
chlorobutanol, combinations |
0‑L |
A05
|
BILE AND LIVER THERAPY
|
WHO Anatomical Therapeutic Chemical classification |
|
BILE AND LIVER THERAPY |
0‑L |
A05A
|
BILE THERAPY
|
WHO Anatomical Therapeutic Chemical classification |
|
BILE THERAPY |
0‑L |
A05AA
|
Bile acid preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Bile acid preparations |
0‑L |
A05AA01
|
chenodeoxycholic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
chenodeoxycholic acid |
0‑L |
A05AA02
|
ursodeoxycholic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
ursodeoxycholic acid |
0‑L |
A05AA03
|
cholic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
cholic acid |
0‑L |
A05AA04
|
obeticholic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
obeticholic acid |
0‑L |
A05AB
|
Preparations for biliary tract therapy
|
WHO Anatomical Therapeutic Chemical classification |
|
Preparations for biliary tract therapy |
0‑L |
A05AB01
|
nicotinyl methylamide
|
WHO Anatomical Therapeutic Chemical classification |
|
nicotinyl methylamide |
0‑L |
A05AX
|
Other drugs for bile therapy
|
WHO Anatomical Therapeutic Chemical classification |
|
Other drugs for bile therapy |
0‑L |
A05AX01
|
piprozolin
|
WHO Anatomical Therapeutic Chemical classification |
|
piprozolin |
0‑L |
A05AX02
|
hymecromone
|
WHO Anatomical Therapeutic Chemical classification |
|
hymecromone |
0‑L |
A05AX03
|
cyclobutyrol
|
WHO Anatomical Therapeutic Chemical classification |
|
cyclobutyrol |
0‑L |
A05B
|
LIVER THERAPY, LIPOTROPICS
|
WHO Anatomical Therapeutic Chemical classification |
|
LIVER THERAPY, LIPOTROPICS |
0‑L |
A05BA
|
Liver therapy
|
WHO Anatomical Therapeutic Chemical classification |
|
Liver therapy |
0‑L |
A05BA01
|
arginine glutamate
|
WHO Anatomical Therapeutic Chemical classification |
|
arginine glutamate |
0‑L |
A05BA03
|
silymarin
|
WHO Anatomical Therapeutic Chemical classification |
|
silymarin |
0‑L |
A05BA04
|
citiolone
|
WHO Anatomical Therapeutic Chemical classification |
|
citiolone |
0‑L |
A05BA05
|
epomediol
|
WHO Anatomical Therapeutic Chemical classification |
|
epomediol |
0‑L |
A05BA06
|
ornithine oxoglurate
|
WHO Anatomical Therapeutic Chemical classification |
|
ornithine oxoglurate |
0‑L |
A05BA07
|
tidiacic arginine
|
WHO Anatomical Therapeutic Chemical classification |
|
tidiacic arginine |
0‑L |
A05BA08
|
glycyrrhizic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
glycyrrhizic acid |
0‑L |
A05C
|
DRUGS FOR BILE THERAPY AND LIPOTROPICS IN COMBINATION
|
WHO Anatomical Therapeutic Chemical classification |
|
DRUGS FOR BILE THERAPY AND LIPOTROPICS IN COMBINATION |
0‑L |
A06
|
DRUGS FOR CONSTIPATION
|
WHO Anatomical Therapeutic Chemical classification |
|
DRUGS FOR CONSTIPATION |
0‑L |
A06A
|
DRUGS FOR CONSTIPATION
|
WHO Anatomical Therapeutic Chemical classification |
|
DRUGS FOR CONSTIPATION |
0‑L |
A06AA
|
Softeners, emollients
|
WHO Anatomical Therapeutic Chemical classification |
|
Softeners, emollients |
0‑L |
A06AA01
|
liquid paraffin
|
WHO Anatomical Therapeutic Chemical classification |
|
liquid paraffin |
0‑L |
A06AA02
|
docusate sodium
|
WHO Anatomical Therapeutic Chemical classification |
|
docusate sodium |
0‑L |
A06AA51
|
liquid paraffin, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
liquid paraffin, combinations |
0‑L |
A06AB
|
Contact laxatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Contact laxatives |
0‑L |
A06AB01
|
oxyphenisatine
|
WHO Anatomical Therapeutic Chemical classification |
|
oxyphenisatine |
0‑L |
A06AB02
|
bisacodyl
|
WHO Anatomical Therapeutic Chemical classification |
|
bisacodyl |
0‑L |
A06AB03
|
dantron
|
WHO Anatomical Therapeutic Chemical classification |
|
dantron |
0‑L |
A06AB04
|
phenolphthalein
|
WHO Anatomical Therapeutic Chemical classification |
|
phenolphthalein |
0‑L |
A06AB05
|
castor oil
|
WHO Anatomical Therapeutic Chemical classification |
|
castor oil |
0‑L |
A06AB06
|
senna glycosides
|
WHO Anatomical Therapeutic Chemical classification |
|
senna glycosides |
0‑L |
A06AB07
|
cascara
|
WHO Anatomical Therapeutic Chemical classification |
|
cascara |
0‑L |
A06AB08
|
sodium picosulfate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium picosulfate |
0‑L |
A06AB09
|
bisoxatin
|
WHO Anatomical Therapeutic Chemical classification |
|
bisoxatin |
0‑L |
A06AB20
|
contact laxatives in combination
|
WHO Anatomical Therapeutic Chemical classification |
|
contact laxatives in combination |
0‑L |
A06AB30
|
contact laxatives in combination with belladonna alkaloids
|
WHO Anatomical Therapeutic Chemical classification |
|
contact laxatives in combination with belladonna alkaloids |
0‑L |
A06AB52
|
bisacodyl, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
bisacodyl, combinations |
0‑L |
A06AB53
|
dantron, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
dantron, combinations |
0‑L |
A06AB56
|
senna glycosides, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
senna glycosides, combinations |
0‑L |
A06AB57
|
cascara, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
cascara, combinations |
0‑L |
A06AB58
|
sodium picosulfate, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium picosulfate, combinations |
0‑L |
A06AC
|
Bulk-forming laxatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Bulk-forming laxatives |
0‑L |
A06AC01
|
ispaghula (psylla seeds)
|
WHO Anatomical Therapeutic Chemical classification |
|
ispaghula (psylla seeds) |
0‑L |
A06AC02
|
ethulose
|
WHO Anatomical Therapeutic Chemical classification |
|
ethulose |
0‑L |
A06AC03
|
sterculia
|
WHO Anatomical Therapeutic Chemical classification |
|
sterculia |
0‑L |
A06AC05
|
linseed
|
WHO Anatomical Therapeutic Chemical classification |
|
linseed |
0‑L |
A06AC06
|
methylcellulose
|
WHO Anatomical Therapeutic Chemical classification |
|
methylcellulose |
0‑L |
A06AC07
|
triticum (wheat fibre)
|
WHO Anatomical Therapeutic Chemical classification |
|
triticum (wheat fibre) |
0‑L |
A06AC08
|
polycarbophil calcium
|
WHO Anatomical Therapeutic Chemical classification |
|
polycarbophil calcium |
0‑L |
A06AC51
|
ispaghula, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
ispaghula, combinations |
0‑L |
A06AC53
|
sterculia, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
sterculia, combinations |
0‑L |
A06AC55
|
linseed, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
linseed, combinations |
0‑L |
A06AD
|
Osmotically acting laxatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Osmotically acting laxatives |
0‑L |
A06AD01
|
magnesium carbonate
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium carbonate |
0‑L |
A06AD02
|
magnesium oxide
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium oxide |
0‑L |
A06AD03
|
magnesium peroxide
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium peroxide |
0‑L |
A06AD04
|
magnesium sulfate
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium sulfate |
0‑L |
A06AD10
|
mineral salts in combination
|
WHO Anatomical Therapeutic Chemical classification |
|
mineral salts in combination |
0‑L |
A06AD11
|
lactulose
|
WHO Anatomical Therapeutic Chemical classification |
|
lactulose |
0‑L |
A06AD12
|
lactitol
|
WHO Anatomical Therapeutic Chemical classification |
|
lactitol |
0‑L |
A06AD13
|
sodium sulfate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium sulfate |
0‑L |
A06AD14
|
pentaerithrityl
|
WHO Anatomical Therapeutic Chemical classification |
|
pentaerithrityl |
0‑L |
A06AD15
|
macrogol
|
WHO Anatomical Therapeutic Chemical classification |
|
macrogol |
0‑L |
A06AD16
|
mannitol
|
WHO Anatomical Therapeutic Chemical classification |
|
mannitol |
0‑L |
A06AD17
|
sodium phosphate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium phosphate |
0‑L |
A06AD18
|
sorbitol
|
WHO Anatomical Therapeutic Chemical classification |
|
sorbitol |
0‑L |
A06AD19
|
magnesium citrate
|
WHO Anatomical Therapeutic Chemical classification |
|
magnesium citrate |
0‑L |
A06AD21
|
sodium tartrate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium tartrate |
0‑L |
A06AD61
|
lactulose, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
lactulose, combinations |
0‑L |
A06AD65
|
macrogol, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
macrogol, combinations |
0‑L |
A06AG
|
Enemas
|
WHO Anatomical Therapeutic Chemical classification |
|
Enemas |
0‑L |
A06AG01
|
sodium phosphate
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium phosphate |
0‑L |
A06AG02
|
bisacodyl
|
WHO Anatomical Therapeutic Chemical classification |
|
bisacodyl |
0‑L |
A06AG03
|
dantron, incl. combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
dantron, incl. combinations |
0‑L |
A06AG04
|
glycerol
|
WHO Anatomical Therapeutic Chemical classification |
|
glycerol |
0‑L |
A06AG06
|
oil
|
WHO Anatomical Therapeutic Chemical classification |
|
oil |
0‑L |
A06AG07
|
sorbitol
|
WHO Anatomical Therapeutic Chemical classification |
|
sorbitol |
0‑L |
A06AG10
|
docusate sodium, incl. combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
docusate sodium, incl. combinations |
0‑L |
A06AG11
|
sodium lauryl sulfoacetate, incl. combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
sodium lauryl sulfoacetate, incl. combinations |
0‑L |
A06AG20
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
0‑L |
A06AH
|
Peripheral opioid receptor antagonists
|
WHO Anatomical Therapeutic Chemical classification |
|
Peripheral opioid receptor antagonists |
0‑L |
A06AH01
|
methylnaltrexone bromide
|
WHO Anatomical Therapeutic Chemical classification |
|
methylnaltrexone bromide |
0‑L |
A06AH02
|
alvimopan
|
WHO Anatomical Therapeutic Chemical classification |
|
alvimopan |
0‑L |
A06AH03
|
naloxegol
|
WHO Anatomical Therapeutic Chemical classification |
|
naloxegol |
0‑L |
A06AH04
|
naloxone
|
WHO Anatomical Therapeutic Chemical classification |
|
naloxone |
0‑L |
A06AX
|
Other drugs for constipation
|
WHO Anatomical Therapeutic Chemical classification |
|
Other drugs for constipation |
0‑L |
A06AX01
|
glycerol
|
WHO Anatomical Therapeutic Chemical classification |
|
glycerol |
0‑L |
A06AX02
|
carbon dioxide producing drugs
|
WHO Anatomical Therapeutic Chemical classification |
|
carbon dioxide producing drugs |
0‑L |
A06AX03
|
lubiprostone
|
WHO Anatomical Therapeutic Chemical classification |
|
lubiprostone |
0‑L |
A06AX04
|
linaclotide
|
WHO Anatomical Therapeutic Chemical classification |
|
linaclotide |
0‑L |
A06AX05
|
prucalopride
|
WHO Anatomical Therapeutic Chemical classification |
|
prucalopride |
0‑L |
A06AX06
|
tegaserod
|
WHO Anatomical Therapeutic Chemical classification |
|
tegaserod |
0‑L |
A07
|
ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS |
0‑L |
A07A
|
INTESTINAL ANTIINFECTIVES
|
WHO Anatomical Therapeutic Chemical classification |
|
INTESTINAL ANTIINFECTIVES |
0‑L |
A07AA
|
Antibiotics
|
WHO Anatomical Therapeutic Chemical classification |
|
Antibiotics |
0‑L |
A07AA01
|
neomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
neomycin |
0‑L |
A07AA02
|
nystatin
|
WHO Anatomical Therapeutic Chemical classification |
|
nystatin |
0‑L |
A07AA03
|
natamycin
|
WHO Anatomical Therapeutic Chemical classification |
|
natamycin |
0‑L |
A07AA04
|
streptomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
streptomycin |
0‑L |
A07AA05
|
polymyxin B
|
WHO Anatomical Therapeutic Chemical classification |
|
polymyxin B |
0‑L |
A07AA06
|
paromomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
paromomycin |
0‑L |
A07AA07
|
amphotericin B
|
WHO Anatomical Therapeutic Chemical classification |
|
amphotericin B |
0‑L |
A07AA08
|
kanamycin
|
WHO Anatomical Therapeutic Chemical classification |
|
kanamycin |
0‑L |
A07AA09
|
vancomycin
|
WHO Anatomical Therapeutic Chemical classification |
|
vancomycin |
0‑L |
A07AA10
|
colistin
|
WHO Anatomical Therapeutic Chemical classification |
|
colistin |
0‑L |
A07AA11
|
rifaximin
|
WHO Anatomical Therapeutic Chemical classification |
|
rifaximin |
0‑L |
A07AA12
|
fidaxomicin
|
WHO Anatomical Therapeutic Chemical classification |
|
fidaxomicin |
0‑L |
A07AA51
|
neomycin, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
neomycin, combinations |
0‑L |
A07AA54
|
streptomycin, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
streptomycin, combinations |
0‑L |
A07AB
|
Sulfonamides
|
WHO Anatomical Therapeutic Chemical classification |
|
Sulfonamides |
0‑L |
A07AB02
|
phthalylsulfathiazole
|
WHO Anatomical Therapeutic Chemical classification |
|
phthalylsulfathiazole |
0‑L |
A07AB03
|
sulfaguanidine
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfaguanidine |
0‑L |
A07AB04
|
succinylsulfathiazole
|
WHO Anatomical Therapeutic Chemical classification |
|
succinylsulfathiazole |
0‑L |
A07AC
|
Imidazole derivatives
|
WHO Anatomical Therapeutic Chemical classification |
|
Imidazole derivatives |
0‑L |
A07AC01
|
miconazole
|
WHO Anatomical Therapeutic Chemical classification |
|
miconazole |
0‑L |
A07AX
|
Other intestinal antiinfectives
|
WHO Anatomical Therapeutic Chemical classification |
|
Other intestinal antiinfectives |
0‑L |
A07AX01
|
broxyquinoline
|
WHO Anatomical Therapeutic Chemical classification |
|
broxyquinoline |
0‑L |
A07AX02
|
acetarsol
|
WHO Anatomical Therapeutic Chemical classification |
|
acetarsol |
0‑L |
A07AX03
|
nifuroxazide
|
WHO Anatomical Therapeutic Chemical classification |
|
nifuroxazide |
0‑L |
A07AX04
|
nifurzide
|
WHO Anatomical Therapeutic Chemical classification |
|
nifurzide |
0‑L |
A07B
|
INTESTINAL ADSORBENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
INTESTINAL ADSORBENTS |
0‑L |
A07BA
|
Charcoal preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Charcoal preparations |
0‑L |
A07BA01
|
medicinal charcoal
|
WHO Anatomical Therapeutic Chemical classification |
|
medicinal charcoal |
0‑L |
A07BA51
|
medicinal charcoal, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
medicinal charcoal, combinations |
0‑L |
A07BB
|
Bismuth preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Bismuth preparations |
0‑L |
A07BC
|
Other intestinal adsorbents
|
WHO Anatomical Therapeutic Chemical classification |
|
Other intestinal adsorbents |
0‑L |
A07BC01
|
pectin
|
WHO Anatomical Therapeutic Chemical classification |
|
pectin |
0‑L |
A07BC02
|
kaolin
|
WHO Anatomical Therapeutic Chemical classification |
|
kaolin |
0‑L |
A07BC03
|
crospovidone
|
WHO Anatomical Therapeutic Chemical classification |
|
crospovidone |
0‑L |
A07BC04
|
attapulgite
|
WHO Anatomical Therapeutic Chemical classification |
|
attapulgite |
0‑L |
A07BC05
|
diosmectite
|
WHO Anatomical Therapeutic Chemical classification |
|
diosmectite |
0‑L |
A07BC30
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
0‑L |
A07BC54
|
attapulgite, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
attapulgite, combinations |
0‑L |
A07C
|
ELECTROLYTES WITH CARBOHYDRATES
|
WHO Anatomical Therapeutic Chemical classification |
|
ELECTROLYTES WITH CARBOHYDRATES |
0‑L |
A07CA
|
Oral rehydration salt formulations
|
WHO Anatomical Therapeutic Chemical classification |
|
Oral rehydration salt formulations |
0‑L |
A07D
|
ANTIPROPULSIVES
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIPROPULSIVES |
0‑L |
A07DA
|
Antipropulsives
|
WHO Anatomical Therapeutic Chemical classification |
|
Antipropulsives |
0‑L |
A07DA01
|
diphenoxylate
|
WHO Anatomical Therapeutic Chemical classification |
|
diphenoxylate |
0‑L |
A07DA02
|
opium
|
WHO Anatomical Therapeutic Chemical classification |
|
opium |
0‑L |
A07DA03
|
loperamide
|
WHO Anatomical Therapeutic Chemical classification |
|
loperamide |
0‑L |
A07DA04
|
difenoxin
|
WHO Anatomical Therapeutic Chemical classification |
|
difenoxin |
0‑L |
A07DA05
|
loperamide oxide
|
WHO Anatomical Therapeutic Chemical classification |
|
loperamide oxide |
0‑L |
A07DA06
|
eluxadoline
|
WHO Anatomical Therapeutic Chemical classification |
|
eluxadoline |
0‑L |
A07DA52
|
morphine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
morphine, combinations |
0‑L |
A07DA53
|
loperamide, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
loperamide, combinations |
0‑L |
A07E
|
INTESTINAL ANTIINFLAMMATORY AGENTS
|
WHO Anatomical Therapeutic Chemical classification |
|
INTESTINAL ANTIINFLAMMATORY AGENTS |
0‑L |
A07EA
|
Corticosteroids acting locally
|
WHO Anatomical Therapeutic Chemical classification |
|
Corticosteroids acting locally |
0‑L |
A07EA01
|
prednisolone
|
WHO Anatomical Therapeutic Chemical classification |
|
prednisolone |
0‑L |
A07EA02
|
hydrocortisone
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrocortisone |
0‑L |
A07EA03
|
prednisone
|
WHO Anatomical Therapeutic Chemical classification |
|
prednisone |
0‑L |
A07EA04
|
betamethasone
|
WHO Anatomical Therapeutic Chemical classification |
|
betamethasone |
0‑L |
A07EA05
|
tixocortol
|
WHO Anatomical Therapeutic Chemical classification |
|
tixocortol |
0‑L |
A07EA06
|
budesonide
|
WHO Anatomical Therapeutic Chemical classification |
|
budesonide |
0‑L |
A07EA07
|
beclometasone
|
WHO Anatomical Therapeutic Chemical classification |
|
beclometasone |
0‑L |
A07EB
|
Antiallergic agents, excl. corticosteroids
|
WHO Anatomical Therapeutic Chemical classification |
|
Antiallergic agents, excl. corticosteroids |
0‑L |
A07EB01
|
cromoglicic acid
|
WHO Anatomical Therapeutic Chemical classification |
|
cromoglicic acid |
0‑L |
A07EC
|
Aminosalicylic acid and similar agents
|
WHO Anatomical Therapeutic Chemical classification |
|
Aminosalicylic acid and similar agents |
0‑L |
A07EC01
|
sulfasalazine
|
WHO Anatomical Therapeutic Chemical classification |
|
sulfasalazine |
0‑L |
A07EC02
|
mesalazine
|
WHO Anatomical Therapeutic Chemical classification |
|
mesalazine |
0‑L |
A07EC03
|
olsalazine
|
WHO Anatomical Therapeutic Chemical classification |
|
olsalazine |
0‑L |
A07EC04
|
balsalazide
|
WHO Anatomical Therapeutic Chemical classification |
|
balsalazide |
0‑L |
A07F
|
ANTIDIARRHEAL MICROORGANISMS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIDIARRHEAL MICROORGANISMS |
0‑L |
A07FA
|
Antidiarrheal microorganisms
|
WHO Anatomical Therapeutic Chemical classification |
|
Antidiarrheal microorganisms |
0‑L |
A07FA01
|
lactic acid producing organisms
|
WHO Anatomical Therapeutic Chemical classification |
|
lactic acid producing organisms |
0‑L |
A07FA02
|
saccharomyces boulardii
|
WHO Anatomical Therapeutic Chemical classification |
|
saccharomyces boulardii |
0‑L |
A07FA51
|
lactic acid producing organisms, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
lactic acid producing organisms, combinations |
0‑L |
A07X
|
OTHER ANTIDIARRHEALS
|
WHO Anatomical Therapeutic Chemical classification |
|
OTHER ANTIDIARRHEALS |
0‑L |
A07XA
|
Other antidiarrheals
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antidiarrheals |
0‑L |
A07XA01
|
albumin tannate
|
WHO Anatomical Therapeutic Chemical classification |
|
albumin tannate |
0‑L |
A07XA02
|
ceratonia
|
WHO Anatomical Therapeutic Chemical classification |
|
ceratonia |
0‑L |
A07XA03
|
calcium compounds
|
WHO Anatomical Therapeutic Chemical classification |
|
calcium compounds |
0‑L |
A07XA04
|
racecadotril
|
WHO Anatomical Therapeutic Chemical classification |
|
racecadotril |
0‑L |
A07XA51
|
albumin tannate, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
albumin tannate, combinations |
0‑L |
A08
|
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS |
0‑L |
A08A
|
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
|
WHO Anatomical Therapeutic Chemical classification |
|
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS |
0‑L |
A08AA
|
Centrally acting antiobesity products
|
WHO Anatomical Therapeutic Chemical classification |
|
Centrally acting antiobesity products |
0‑L |
A08AA01
|
phentermine
|
WHO Anatomical Therapeutic Chemical classification |
|
phentermine |
0‑L |
A08AA02
|
fenfluramine
|
WHO Anatomical Therapeutic Chemical classification |
|
fenfluramine |
0‑L |
A08AA03
|
amfepramone
|
WHO Anatomical Therapeutic Chemical classification |
|
amfepramone |
0‑L |
A08AA04
|
dexfenfluramine
|
WHO Anatomical Therapeutic Chemical classification |
|
dexfenfluramine |
0‑L |
A08AA05
|
mazindol
|
WHO Anatomical Therapeutic Chemical classification |
|
mazindol |
0‑L |
A08AA06
|
etilamfetamine
|
WHO Anatomical Therapeutic Chemical classification |
|
etilamfetamine |
0‑L |
A08AA07
|
cathine
|
WHO Anatomical Therapeutic Chemical classification |
|
cathine |
0‑L |
A08AA08
|
clobenzorex
|
WHO Anatomical Therapeutic Chemical classification |
|
clobenzorex |
0‑L |
A08AA09
|
mefenorex
|
WHO Anatomical Therapeutic Chemical classification |
|
mefenorex |
0‑L |
A08AA10
|
sibutramine
|
WHO Anatomical Therapeutic Chemical classification |
|
sibutramine |
0‑L |
A08AA11
|
lorcaserin
|
WHO Anatomical Therapeutic Chemical classification |
|
lorcaserin |
0‑L |
A08AA56
|
ephedrine, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
ephedrine, combinations |
0‑L |
A08AA62
|
bupropion and naltrexone
|
WHO Anatomical Therapeutic Chemical classification |
|
bupropion and naltrexone |
0‑L |
A08AB
|
Peripherally acting antiobesity products
|
WHO Anatomical Therapeutic Chemical classification |
|
Peripherally acting antiobesity products |
0‑L |
A08AB01
|
orlistat
|
WHO Anatomical Therapeutic Chemical classification |
|
orlistat |
0‑L |
A08AX
|
Other antiobesity drugs
|
WHO Anatomical Therapeutic Chemical classification |
|
Other antiobesity drugs |
0‑L |
A08AX01
|
rimonabant
|
WHO Anatomical Therapeutic Chemical classification |
|
rimonabant |
0‑L |
A09
|
DIGESTIVES, INCL. ENZYMES
|
WHO Anatomical Therapeutic Chemical classification |
|
DIGESTIVES, INCL. ENZYMES |
0‑L |
A09A
|
DIGESTIVES, INCL. ENZYMES
|
WHO Anatomical Therapeutic Chemical classification |
|
DIGESTIVES, INCL. ENZYMES |
0‑L |
A09AA
|
Enzyme preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Enzyme preparations |
0‑L |
A09AA01
|
diastase
|
WHO Anatomical Therapeutic Chemical classification |
|
diastase |
0‑L |
A09AA02
|
multienzymes (lipase, protease etc.)
|
WHO Anatomical Therapeutic Chemical classification |
|
multienzymes (lipase, protease etc.) |
0‑L |
A09AA03
|
pepsin
|
WHO Anatomical Therapeutic Chemical classification |
|
pepsin |
0‑L |
A09AA04
|
tilactase
|
WHO Anatomical Therapeutic Chemical classification |
|
tilactase |
0‑L |
A09AB
|
Acid preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
Acid preparations |
0‑L |
A09AB01
|
glutamic acid hydrochloride
|
WHO Anatomical Therapeutic Chemical classification |
|
glutamic acid hydrochloride |
0‑L |
A09AB02
|
betaine hydrochloride
|
WHO Anatomical Therapeutic Chemical classification |
|
betaine hydrochloride |
0‑L |
A09AB03
|
hydrochloric acid
|
WHO Anatomical Therapeutic Chemical classification |
|
hydrochloric acid |
0‑L |
A09AB04
|
citric acid
|
WHO Anatomical Therapeutic Chemical classification |
|
citric acid |
0‑L |
A09AC
|
Enzyme and acid preparations, combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
Enzyme and acid preparations, combinations |
0‑L |
A09AC01
|
pepsin and acid preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
pepsin and acid preparations |
0‑L |
A09AC02
|
multienzymes and acid preparations
|
WHO Anatomical Therapeutic Chemical classification |
|
multienzymes and acid preparations |
0‑L |
A10
|
DRUGS USED IN DIABETES
|
WHO Anatomical Therapeutic Chemical classification |
|
DRUGS USED IN DIABETES |
0‑L |
A10A
|
INSULINS AND ANALOGUES
|
WHO Anatomical Therapeutic Chemical classification |
|
INSULINS AND ANALOGUES |
0‑L |
A10AB
|
Insulins and analogues for injection, fast-acting
|
WHO Anatomical Therapeutic Chemical classification |
|
Insulins and analogues for injection, fast-acting |
0‑L |
A10AB01
|
insulin (human)
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin (human) |
0‑L |
A10AB02
|
insulin (beef)
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin (beef) |
0‑L |
A10AB03
|
insulin (pork)
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin (pork) |
0‑L |
A10AB04
|
insulin lispro
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin lispro |
0‑L |
A10AB05
|
insulin aspart
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin aspart |
0‑L |
A10AB06
|
insulin glulisine
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin glulisine |
0‑L |
A10AB30
|
combinations
|
WHO Anatomical Therapeutic Chemical classification |
|
combinations |
0‑L |
A10AC
|
Insulins and analogues for injection, intermediate-acting
|
WHO Anatomical Therapeutic Chemical classification |
|
Insulins and analogues for injection, intermediate-acting |
0‑L |
A10AC01
|
insulin (human)
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin (human) |
0‑L |
A10AC02
|
insulin (beef)
|
WHO Anatomical Therapeutic Chemical classification |
|
insulin (beef) |
This value set has 6082 codes in it. In order to keep the publication size manageable,
only a selection (500 codes) of the whole set of codes is shown.
|
|